October 29, 2019Open Access

Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Among adults infected with M. tuberculosis, vaccination with M72/AS01E elicited an immune response and provided protection against progression to pulmonary tuberculosis disease for at least 3 years. (Funded by GlaxoSmithKline Biologicals and Aeras; ClinicalTrials.gov number, NCT01755598.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Tait et al. (Tue,) studied this question.

synapsesocial.com/papers/69d99b64a1d151c65f684949 https://doi.org/https://doi.org/10.1056/nejmoa1909953

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults2018 · 48 citations
2Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial2012 · 160 citations
3WHO preferred product characteristics for new vaccines against tuberculosis2018 · 48 citations
4Phase 2b Controlled Trial of M72/AS01 <sub>E</sub> Vaccine to Prevent Tuberculosis2018 · 412 citations
5A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults2016 · 62 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo